Why the Nuix (ASX:NXL) share price crashed 20% lower in June

It was another disappointing month for the Nuix share price…

| More on:
share price plummeting down

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nuix Ltd (ASX: NXL) share price was one of the worst performers on the S&P/ASX 200 Index (ASX: XJO) for a second month in a row in June.

The investigative analytics and intelligence software provider's shares followed up a 33% decline in May with a disappointing 20% decline in June.

This means the Nuix share price is now down 73% since the start of the year.

Why did the Nuix share price crash lower in June?

Investors were heading to the exits in their droves last month following yet another series of disappointing developments.

The first actually happened on 31 May but continued to hang over the company in the early stages of June. That development was yet another downgrade to its guidance.

Nuix revealed that it is now expecting pro forma revenue of $173 million to $182 million in FY 2021. This compares to its 21 April guidance of $180 million to $185 million. Similarly, it is now forecasting annualised contract value (ACV) in the range of $165 million to $172 million. This is down from its previous guidance of $168 million to $177 million.

Management blamed this on the timing of the closure of some upsell opportunities and new potential customers. In addition, it notes that there remains uncertainty in relation to both the structure and timing of deals with a small number of large customers.

What else weighed on its shares?

Also weighing on the Nuix share price was the exit of several executives and news of police raids on its offices. Those police raids later led to a criminal investigation into insider trading allegations by its departed chief financial officer Stephen Doyle.

The court papers show that Doyle and his brother are accused of trading Nuix shares with knowledge of inside information over January and February this year. This was before the Nuix share price crashed lower following its shock guidance downgrade.

Nuix chair, Jeffrey Bleich, said: "We are genuinely disturbed by the allegations concerning Mr Doyle and will fully assist ASIC in getting to the bottom of that matter."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Nuix Pty Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »